Table 3.
Crude and adjusted rate ratios for the association between the use of cardiac glycosides and lung cancer by varying the lag period to 6 months and 2 years and by additionally adjusting for sexual hormone intake in women
| Sensitivity analysis | Cases | Controls | Crude RR | Adjusted RR (95% CI) a |
|---|---|---|---|---|
| 6-month lag period | 1423 | 14,166 | ||
| No use, n (%) | 997 (70.1) | 9843 (69.5) | 1.00 | 1.00 (Reference) |
| Ever use, n (%) | 426 (29.9) | 4323 (30.5) | 0.97 | 1.08 (0.94 - 1.24) |
| 2-year lag period | 990 | 9850 | ||
| No use, n (%) | 703 (71.0) | 6815 (69.2) | 1.00 | 1.00 (Reference) |
| Ever use, n (%) | 287 (29.0) | 3035 (30.8) | 0.91 | 1.02 (0.86 - 1.20) |
| Additionally adjusting for HRT/OC use in women | 419 | 4183 | ||
| No use, n (%) | 295 (70.4) | 2828 (67.6) | 1.00 | 1.00 (Reference) |
| Ever use, n (%) | 124 (29.6) | 1355 (32.4) | 0.88 | 0.97 (0.74 - 1.27) |
aAdjusted on smoking status BMI indication of CG use excessive alcohol use history of tobacco-related conditions history of lung diseases factors associated with sexual hormonal disorders drugs potentially associated with lung cancer (statins aspirin oral anticoagulants and antiplatelets non-steroidal anti-inflammatory drugs anti-hypertensives oral bisphosphonates anti-diabetic drugs) and amiodarone.
RR Rate ratio, HRT Hormone replacement therapy, OC Oral contraceptive).